NCT00555035已完成1 期
A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 in Healthy Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Blood levels of drug over 72 hours. Laboratory test results over 72 hours Vital signs, ECG results over 72 hours
研究概览
简要总结
To determine safety, tolerability and pharmacokinetics of GSK1349572
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Blood levels of drug over 72 hours. Laboratory test results over 72 hours Vital signs, ECG results over 72 hours
时间窗: 72 hours.
次要结局
- GSK1349572 PK parameters: absorption lag time (tlag), and apparent clearance (CL/F) following single dose administration.
- AUC(0-¥), AUC(0-t), Cmax, and C24 following single dose administration at different doses for the assessment of dose proportionality.
- Dose proportionality over 72 hours(72 hours.)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
GSK1247303 First Time in Human StudyHealthy SubjectsNCT00651079GlaxoSmithKline58
已完成
1 期
GSK706769 Repeat Dose StudyInfection, Human Immunodeficiency VirusNCT00711386GlaxoSmithKline40
终止
1 期
GSK706769 A First Time in Human Study For Males and FemalesHealthy SubjectsNCT00539201GlaxoSmithKline34
已完成
2 期
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT00950807GlaxoSmithKline176
已完成
1 期
Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT01381536GlaxoSmithKline12